To be screened or not to be screened? Modeling the consequences of PSA screening for the individual.
BACKGROUND
Screening with prostate-specific antigen (PSA) can reduce prostate cancer mortality, but may advance diagnosis and treatment in time and lead to overdetection and overtreatment. We estimated benefits and adverse effects of PSA screening for individuals who are deciding whether or not to be screened.


METHODS
Using a microsimulation model, we estimated lifetime probabilities of prostate cancer diagnosis and death, overall life expectancy and expected time to diagnosis, both with and without screening. We calculated anticipated loss in quality of life due to prostate cancer diagnosis and treatment that would be acceptable to decide in favour of screening.


RESULTS
Men who were screened had a gain in life expectancy of 0.08 years but their expected time to diagnosis decreased by 1.53 life-years. Of the screened men, 0.99% gained on average 8.08 life-years and for 17.43% expected time to diagnosis decreased by 8.78 life-years. These figures imply that the anticipated loss in quality of life owing to diagnosis and treatment should not exceed 4.8%, for screening to have a positive effect on quality-adjusted life expectancy.


CONCLUSIONS
The decision to be screened should depend on personal preferences. The negative impact of screening might be reduced by screening men who are more willing to accept the side effects from treatment.
Department of Public Health, Erasmus Medical Center, PO Box 2040, Rotterdam 3000 CA, The Netherlands. e.m.wever@erasmusmc.nl
E M
EM
Wever
J
J
Hugosson
E A M
EA
Heijnsdijk
C H
CH
Bangma
G
G
Draisma
H J
HJ
de Koning
D000368:Aged; D015331:Cohort Studies; D055088:Early Detection of Cancer / Q000379:methods; D006801:Humans; D008017:Life Expectancy; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D017430:Prostate-Specific Antigen / Q000032:analysis*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D011788:Quality of Life; D015996:Survival Rate
D017430:Prostate-Specific Antigen